| Name | Title | Contact Details |
|---|
As one of the largest and fastest-growing Emergency and Hospital Medicine groups in the nation, we partner with more than 5,000 world-class providers who treat more than 6 million patients annually. Physician-led, our team consists of motivated, personable, highly qualified people interested in putting the patient first. We’re committed to doing the right thing for the patients, physicians, and hospitals we serve. Which is why 98% of our physicians recommend us to colleagues and friends. William C. Schumacher, M.D., a board certified emergency medicine physician, formally founded the Schumacher Group in 1994. The philosophy behind Schumacher Group`s founding was based on his belief that there was a better way to deliver and manage emergency medical services in the hospital environment. That `better way` is embodied in our founding mission. The Schumacher Group became known as Schumacher Clinical Partners in 2016.
Arizona Spinal Cord Injury Association is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cedar provides a smarter way for hospitals, health systems and medical groups to manage the patient payment ecosystem. Our platform delivers modern intelligence to alleviate collections challenges, dramatically improve billing operations and ensure a personalized billing experience for patients. Most revenue cycle solutions today look at only one or two transactional aspects of patient payments. We believe that the focus instead should be on improving the overall experience of patient billing and engagement. Together with the leading medical groups and hospitals across the country, we are elevating the patient payment experience.
Mahaska Health Partnership is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Oskaloosa, IA. To find more information about Mahaska Health Partnership, please visit www.mahaskahealth.org
SCYNEXIS, Inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. Our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. We are developing our lead product candidate, SCY-078, a novel antifungal in Phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.